Expert Updates on the Latest in the Development of Weekly Insulin Formulations-Expert Updates on the Latest Advances in the Development of Weekly Insulin Formulations

Expert Updates on the Latest Advances in the Development of Weekly Insulin Formulations

Video Transcription

Video Summary

Summary:<br /><br />The video content discusses two separate studies focusing on different once-weekly insulin formulations for the treatment of type 2 diabetes. The first study examines the use of Epsitora in comparison to daily basal insulins such as insulin Degladec and insulin glargine. The results show that Epsitora provides similar or improved glucose control without an increased risk of hypoglycemia. However, weight gain may still occur. The convenience of once-weekly dosing is highlighted, and it is suggested that this regimen may improve patient adherence.<br /><br />The second study discusses the use of iCUDEC, another once-weekly insulin formulation. It is found to offer similar advantages in glucose control and low rates of hypoglycemia compared to daily basal insulins. The potential for pairing iCUDEC with GLP-1 receptor agonists is also mentioned.<br /><br />Both studies acknowledge the need for further data and real-world experience with once-weekly insulin formulations. While the convenience of these formulations is emphasized, the video also notes that more research is required to fully understand their benefits and limitations.<br /><br />Credits:<br /><br />The video features experts Rodolfo Galindo, Dr. Juan Frias, and Professor Carol Wieschan.

Asset Caption

On-Demand

Keywords

once-weekly insulin formulations

type 2 diabetes

Epsitora

insulin Degladec

insulin glargine

glucose control

hypoglycemia

weight gain

patient adherence

iCUDEC

GLP-1 receptor agonists


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274